Katharine Yang

Cardiologist

[Davide Capodanno @DFCapodanno]

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor.

1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA
2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease
3. API-CAT = Reduced-dose versus full-dose apixaban in cancer with VTE
4. FARES-II = Four-factor prothrombin complex in cardiac surgery
5. REVERSE-IT = Bentracimab in uncontrolled bleeding or requiring urgent surgery or invasive procedures
6. RIVAWAR = Rivaroxaban versus warfarin in left ventricular thrombus after MI
7. SOUL = Oral semaglutide in type 2 diabetes with ASCVD and/or CKD
8. ADVANCE-HTN = Lorundrostat in uncontrolled hypertension
9. DapaTAVI = Dapagliflozin in transcatheter heart valve treatment
10. MIGHTy-Heart = Two strategies for improving transition to home after heart failure hospitalization
11. FRESH-UP = Liberal versus restrictive fluid intake in chronic heart failure in outpatient setting
12. FAIR-HF2 = Intravenous iron in heart failure with iron deficiency
13. PROTECT-TAVI = Embolic protection in TAVI
14. ALIGN-AR = Dedicated transcatheter aortic valve in aortic regurgitation
15. Evolut Low Risk = TAVI in low-risk
16. FLAVOUR II = Angiography-derived FFR versus IVUS in PCI
17. TRILUMINATE = Tricuspid transcatheter edge-to-edge repair in tricuspid regurgitation
18. FAME 3 = FFR-guided PCI versus CABG in multivessel disease
19. RACER = Out-of-hospital cardiac arrest during long-distance running events
20. Altshock-2 = Intra-aortic balloon pump in heart failure complicated by cardiogenic shock
21. ECLIPSE = Intravascular imaging to guide PCI of severely calcified lesions in PCI
22. HOST-BR = DAPT duration based on bleeding risk

[American College of Cardiology @ACCinTouch]

Members from #ACCWIC and #ACCCVManage Member Sections developed a toolkit focusing on how to start a heart center for women & how to manage the care of women w/ or at risk for #CVD.

Learn more and access the toolkit here: https://t.co/251d6kcH7m

[Janet Wei MD @JanetWeiMD]

Dr. Ileana Pina shares tips for success to enroll more women in clinical trials:
1) Women in clinical trial leadership
2) Convenience of research measures and enrollment— enroll in clinic and in presence of patient’s families
3) budget for transportation/partner with rideshare

[Katharine Yang @thekatyang]

#ACC24 LBT: DanGer Shock
- 355 Danish/German/UK (79% male) patients post-AMI in cardiogenic shock were randomized to ImpellaCP+standard care vs. standard care only
- Significant ⬇️ 1° endpt of death from any cause at 180d
- But ⬆️ risk of bldg, RRT, sepsis
@CardiacTrials

[Katharine Yang @thekatyang]

@wilzawall @ajay_vaidya @USC_Cardiology @LACUSCResidents Thank you so much, Dr. Lam! 🙏

[Katharine Yang @thekatyang]

Wonderful to see Dr. @ajay_vaidya at #ACC24, my heart failure cardiology attending at @USC_Cardiology and a great clinician-educator, who inspired me to pursue cardiology when I was still an undifferentiated @LACUSCResidents IM resident 🫀🫀🫀
#gratitude
#ACCFIT

[Katharine Yang @thekatyang]

@HarborUCLA Cardiology Representation at #ACC24!!

#ACCFIT with our attending Dr. Chung

Much gratitude to our PD @BudoffMd for enabling us all to attend a 🫀 conference every year! 🙏

[Katharine Yang @thekatyang]

#ACC24 Late Breaking Trial: REDUCE-AMI
- Approx 5000 patients who were post MI and had LVEF >= 50% were randomized to beta blocker vs. no blocker
- Median follow-up of 3.5 years
- No difference in primary endpoint of all-cause death or MI, or secondary endpoints!

@CardiacTrials

[Katharine Yang @thekatyang]

🔥Highlights from the Late breaking SMART trial studying Self-Expanding vs. Balloon-Expandable TAVR in patients with small aortic annuli - that enrolled 75% women! 🔥

#ACC24
@CardiacTrials

[Katharine Yang @thekatyang]

@DrGayatriSK @StanfordVasc @StanfordSurgery @EriFukayaMD @NickLeeper78 Congratulations Gayatri!!! 👏👏👏

[Riya Sam, MD @RiyaSam12]

#AHA22 LBCTs one liners:

1. TRANSFORM-HF: Torsemide was not superior to furosemide in improving survival among patients treated for decompensated HF.

2. DCP: No differences in cardiovascular outcomes between chlorthalidone and HCTZ among elderly veterans with HTN.

[Katharine Yang @thekatyang]

Reunited 🙏
From medical students 👩🏻‍⚕️ to cardiology fellows 🫀!

[Lily N Dastmalchi DO, MA @DrDastmalchi]

The universe works in interesting ways (or maybe it is #MercuryRetrograde lol) @thekatyang and I met as #medstudents #presenters @ACPinternists #ACP2018 and here we are four years later “meeting” again @CMHC_CME #CMHCWomensMC 👯‍♀️🫀#wic #MedTwitter #cardiotwitter

[Katharine Yang @thekatyang]

@DrDastmalchi @ACPinternists @CMHC_CME It was the best surprise ever!! 🙌🙌🙌

[Lily N Dastmalchi DO, MA @DrDastmalchi]

What a beautiful crew of #wic lead by the no other @ErinMichos. Thank you for being such an incredible mentor, leader and advocate in #cvprevention #cardioOB @DrAlaaDiab @jholtzman3 @thekatyang

[Katharine Yang @thekatyang]

Thankful for the great discussions ranging from being a woman cardiologist to women’s CV health with @DrMarthaGulati, especially in regards to more awareness required for CVD in the South Asian community!

[Ahmed Mahmood, MD PhD @AhmedMahmoodMD]

#ACC22 #CardioTwitter Beautiful mix of cardiologist and future cardiologist @ACC22 with Dr. @DrMarthaGulati

[Pamela B Morris MD @PamelaBMorris]

New Besties! #ACC22 ⁦@ACCinTouch⁩ @drharman303 ⁦@DrDonthi⁩ ⁦@thekatyang⁩

[Katharine Yang @thekatyang]

@PamelaBMorris @drharman303 @ditchhaporia @DrDonthi @ACCinTouch Hi new bestie, Pam!!! We were so delighted to get to know you yesterday! A huge CONGRATULATIONS on leading such an inspiring, invigorating, and educational #ACC22 conference this year! 👏👏👏

[Katharine Yang @thekatyang]

Honored to have met ACC President Dr. @ditchhaporia who inspires the next generation of female cardiologists like us! @DrDonthi @drharman303 @ACCinTouch #ACC22 #ACCWIC

[Katharine Yang @thekatyang]

UCSF Cardiac Hospitalists at #ACC22! 🫀

I’ve had an incredible time so far learning about late breaking clinical trials, new ACC guidelines, catching up w old friends, making new ones, and much more.

[BiykemBozkurt @BiykemB]

2022 ACC/AHA/HFSA HF guidelines are out. I would like to thank the writing group members and the the staff for their tireless efforts. We are excited and encourage all clinicians to check it it out . New Recommendations & helpful figures https://t.co/OvVwkSBWFI